(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Athersys (ATHX) said Tuesday its partner Healios completed enrollment in its phase 2/3 trial in Japan evaluating the company's MultiStem cell therapy...
Athersys (ATHX) said Friday that Healios, its partner in Japan, reported positive topline data from its clinical trial assessing the safety and efficacy of...
| Address | 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 |
| Phone | +1.216.431.9900 |
| Number of Employees | 75 |
| Recent SEC Filing | 11/19/2021 4 |
| President, Chief Executive & Operating Officer | William B. J. Lehmann |
| Chief Financial & Accounting Officer | Ivor MacLeod |
| Director, Chief Scientific Officer & Executive VP | John J. Harrington |
| Head-Information Technology & Communications | Rakesh Ramachandran |
| Price Open | $1.08 |
| Previous Close | $1.09 |
| 52 Week Range | $0.92 - 3.03 |
| Market Capitalization | $242.3 M |
| Shares Outstanding | 235.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/24/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.41 |
| Beta vs. S&P 500 | N/A |
| Revenue | $24.3 M |
| Net Profit Margin | -1,442.59% |
| Return on Equity | -268.18% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
